TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14628190
Drug: Conventional selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional selegiline tablets 10 mg
Study: 14628190
Drug: Zydis Selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zydis Selegiline 1.25 mg
Study: 10590283
Drug: Azithromycin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1200 mg/week)
Study: 8829718
Drug: Original trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original trial medication
Study: 8829718
Drug: Continuous use
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous use of psychotropic medication during follow-up
Study: 386061
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg twice a day
Study: 386061
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg twice a day
Study: 386061
Drug: Oxprenolol 80
Normalized name: oxprenolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol 80 mg twice a day
Study: 386061
Drug: Oxprenolol 160
Normalized name: oxprenolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol 160 mg twice a day
Study: 18180581
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment methods for cartilage defects, specific interventions not detailed, timing and methods of treatment unclear.
Study: 18180581
Drug: Natural course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural course of cartilage defects, treatment methods not specified.
Study: 14753327
Drug: Vitremer in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitremer in De‐Re‐ solutions
Study: 9273875
Drug: 5 mg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/m3 zinc oxide
Study: 9273875
Drug: 2.5 mg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/m3 zinc oxide
Study: 7958542
Drug: Glibenclamide 1.75
Normalized name: Glibenclamide 1.75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 1.75 mg
Study: 7958542
Drug: Glibenclamide 3.5
Normalized name: Glibenclamide 3.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 3.5 mg
Study: 7958542
Drug: Glibenclamide 7.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 7.0 mg
Study: 7958542
Drug: AG 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG 1.0 mg
Study: 7958542
Drug: AG 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG 2.0 mg
Study: 7958542
Drug: AG 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG 4.0 mg
Study: 7958542
Drug: Glibenclamide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (all doses)
Study: 7958542
Drug: AG (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG (all doses)
Study: 2885301
Drug: Propranolol (PROP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (PROP, 80 mg twice daily)
Study: 2885301
Drug: Atenolol (ATEN,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (ATEN, 100 mg once a day)
Study: 28454794
Drug: Intravascular ultrasound-guided
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular ultrasound-guided PCI with the novel everolimus-eluting platinum-chromium Synergy stent followed by 4 months of dual antiplatelet therapy (DAPT)
Study: 19154471
Drug: bevacizumab (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: bevacizumab (in combination with interferon)
Study: 2510284
Drug: Rioprostil (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rioprostil (single oral dose)
Study: 2510284
Drug: Rioprostil (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rioprostil (repeated evening doses)
Study: 26150444
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents.
Study: 26150444
Drug: CCRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCRT with docetaxel (20 mg/m(2)) and cisplatin (20 mg/m(2)) administered weekly for 6 weeks.
Study: 26150444
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after CCRT.
Study: 23194084
Drug: Dapagliflozin 2.5
Normalized name: dapagliflozin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 2.5 mg/day
Study: 23194084
Drug: Dapagliflozin 5
Normalized name: dapagliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 5 mg/day
Study: 11147379
Drug: Cisatracurium (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.2 mg/kg) administered IV
Study: 3531953
Drug: 100 IU
Normalized name: Vitamin E 100 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU of salmon calcitonin subcutaneously daily for 28 days
Study: 3531953
Drug: Physiological solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological solution (placebo) administered daily for 28 days
Study: 30409830
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (CYC) for 1 year in SLS I
Study: 30409830
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (CYC) for 1 year followed by 1 year of placebo in SLS II
Study: 24951020
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (60 mg/kg)
Study: 24951020
Drug: Cryoprecipitate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoprecipitate (10 mL/kg)
Study: 22252356
Drug: ID diet
Normalized name: FREE AMINO ACID DIET
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID diet (1,200 mg/hen per day)
Study: 22252356
Drug: SPL diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPL diet (1,010 mg/hen per day)
Study: 22252356
Drug: SP diet
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP diet (600 mg/hen per day)
Study: 22252356
Drug: ID diet
Normalized name: FREE AMINO ACID DIET
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID diet (1,010 mg/hen per day)
Study: 22252356
Drug: IDL diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDL diet (1,200 mg/hen per day)
Study: 20139218
Drug: Empirical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antibiotics
Study: 20139218
Drug: Empirical delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical delayed antibiotics (by 48 hours)
Study: 20139218
Drug: Targeted antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted antibiotics based on high symptom score
Study: 20139218
Drug: Targeted antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted antibiotics based on dipstick results
Study: 20139218
Drug: Targeted antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted antibiotics based on midstream urine analysis
Study: 8169337
Drug: Captopril, 25
Normalized name: Captopril, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 25 mg twice daily
Study: 8826574
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid administration
Study: 24276838
Drug: IV magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV magnesium sulfate (MgSO4) 100 mg/kg every 8 hours
Study: 18343748
Drug: Azithromycin 1
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1 g once daily for 3 days
Study: 18343748
Drug: Amoxicillin-clavulanate 875/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate 875/125 mg twice daily for 7 days
Study: 14712970
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg ginger extract (EV.EXT35; equivalent to 1.5 g of dried ginger) given four times per day for 4 days
Study: 9218089
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg 30 min before meals)
Study: 9218089
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg 60 min before meals)
Study: 29627268
Drug: Communication intervention
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Communication intervention using specific lexical formulations ('do you have 'any' vs. 'some' other concerns?')
Study: 26950204
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of TA-65 (250 U)
Study: 26950204
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of TA-65 (1000 U)
Study: 19368096
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg daily for 6 months
Study: 22864277
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg daily for 6 months
Study: 12202120
Drug: Intraarticular hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular hyaluronic acid (20mg hyaluronic acid/2ml Hyalart) administered via five injections (one injection per week)
Study: 7813259
Drug: PCP score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCP score (PCPSc) assessed on treatment days D0, D3, D7, D14, and D21
Study: 7813259
Drug: LDH levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDH levels during treatment
Study: 22706414
Drug: Dimebon add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimebon add-on treatment
Study: 20050336
Drug: Vancomycin plus
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin plus rifampicin (1 g intravenous every 12 hrs plus 300 mg twice daily by mouth)
Study: 17296974
Drug: Oblimersen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oblimersen (3 mg/kg/d as a 7-day continuous intravenous infusion) plus fludarabine (25 mg/m2/d) and cyclophosphamide (250 mg/m2/d) for 3 days, for up to six cycles.
Study: 17296974
Drug: Fludarabine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (25 mg/m2/d) and cyclophosphamide (250 mg/m2/d) for 3 days (chemotherapy-only group).
Study: 17950856
Drug: Epoetin treatment
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin treatment (control)
Study: 15572737
Drug: Olanzapine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-20 mg/day) combined with ongoing lithium or valproate
Study: 15572737
Drug: Olanzapine co-therapy
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine co-therapy
Study: 11153292
Drug: Ketorolac 10.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10.5 mg subcutaneously at the end of surgery followed by a subcutaneous infusion of 1.75 mg/h for 24 to 36 hours
Study: 1585039
Drug: Scheduled suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled suppository use
Study: 30008080
Drug: Animated instructions
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animated instructions on tablets
Study: 27090301
Drug: Ketamine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (single sub-anesthetic dose)
Study: 25650044
Drug: High-volume CVVH
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume CVVH (4000 mL/h)
Study: 25650044
Drug: Low-volume CVVH
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume CVVH (2000 mL/h)
Study: 25650044
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (before treatment)
Study: 25650044
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (after treatment)
Study: 18852183
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering treatment (including angiotensin-converting enzyme inhibitors, calcium antagonists, angiotensin receptor blockers, diuretics/beta-blockers)
Study: 10732745
Drug: Nine cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine cycles of dose-escalated FEC (fluorouracil, epirubicin, and cyclophosphamide)
Study: 10732745
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of FEC followed by high-dose chemotherapy with alkylating agents (CTCb)
Study: 10732745
Drug: Six cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles of standard intravenous CMF (cyclophosphamide, methotrexate, and fluorouracil)
Study: 9004446
Drug: Three dose
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dose pre-exposure series (days 0, 7, and 28) followed by one booster dose (day 360)
Study: 9004446
Drug: Five dose
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five dose simulated post-exposure series (days 0, 3, 7, 14, and 28)
Study: 9004446
Drug: Lyssavac‐HDC vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyssavac‐HDC vaccine
Study: 1547049
Drug: metoprolol 1
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 1 mg
Study: 1547049
Drug: propranolol 1
Normalized name: propranolol 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol 1 mg
Study: 29235162
Drug: Silymarin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (140 mg, thrice daily for 12 weeks)
Study: 26928828
Drug: Patients feeling
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients feeling relatively healthy by the second day of treatment
Study: 17437727
Drug: Baseline platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline platelet count >= 234 x 10(9)/L
Study: 17437727
Drug: Baseline platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline platelet count < 234 x 10(9)/L
Study: 15126550
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Testosterone Undecanoate (TU)
Study: 15126550
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Testosterone Undecanoate (TU) plus 150 mg Depot Medroxyprogesterone Acetate (DMPA)
Study: 15126550
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Testosterone Undecanoate (TU) plus 300 mg Depot Medroxyprogesterone Acetate (DMPA)
Study: 9458602
Drug: Bass appliance
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bass appliance treatment for 6 months
Study: 7962682
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (7 mg)
Study: 7962682
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (14 mg)
Study: 7962682
Drug: Recovery night
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery night after active nicotine patch
Study: 3619425
Drug: Cefoperazone 1
Normalized name: cefoperazone 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone 1 g
Study: 3619425
Drug: Cefoperazone 2
Normalized name: cefoperazone 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone 2 g
Study: 31742615
Drug: High-Dose Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Vitamin D Supplementation (10,000 IU)
Study: 31742615
Drug: Low-Dose Vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Vitamin D Supplementation (400 IU)
Study: 28960888
Drug: Naldemedine (0.1-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naldemedine (0.1-100 mg)
Study: 28960888
Drug: Naldemedine (3-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naldemedine (3-30 mg once daily for 10 days)
Study: 31753009
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg nicotine gum
Study: 26537155
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg moclobemide
Study: 26537155
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 6 mg nicotine gum and 75 mg moclobemide
Study: 22914208
Drug: 0.005% estriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% estriol vaginal gel (50 μg per application, 1 g daily for 3 weeks, then twice weekly up to 12 weeks)
Study: 17395395
Drug: Olanzapine (OLA)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine (OLA) 2.5 mg for 1 month and 5 mg for 2 months
Study: 16359548
Drug: Efalizumab 1
Normalized name: efalizumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab 1 mg/kg/wk
Study: 15761420
Drug: Efalizumab 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab 2 mg/kg/wk
Study: 15761420
Drug: Efalizumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab (1 or 2 mg/kg)
Study: 6287838
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (20 g/day)
Study: 6287838
Drug: Corn bran
Normalized name: CORN BRAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn bran (20 g/day)
Study: 28345425
Drug: 1% diclofenac/3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% diclofenac/3% menthol gel (n=117)
Study: 9324620
Drug: Intrafusin 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrafusin 10% (10 ml/kg BW/24 h of 10% amino acid solution)
Study: 9324620
Drug: Aminosteril 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminosteril 10% (10 ml/kg BW/24 h of 10% amino acid solution)
Study: 9324620
Drug: Isotonic electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic electrolyte solution (Jonosteril, control group) (10 ml/kg BW/24 h)
Study: 7968327
Drug: Desmopressin acetate
Normalized name: Desmopressin Acetate
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin acetate (0.3 microgram/kg intravenous infusion one hour after cardiopulmonary bypass)
Study: 3884697
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg parenterally
Study: 3884697
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg orally
Study: 3371390
Drug: Metoprolol CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR 100 mg
Study: 3371390
Drug: Metoprolol CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR 200 mg
Study: 15909439
Drug: Topical negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical negative pressure (TNP)
Study: 12945135
Drug: Laser radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser radiation treatment
Study: 19886855
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg to 300 mg
Study: 10862446
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg to 20 mg
Study: 3709379
Drug: Caloric restricted
Normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caloric restricted diet (300 kcal/d) over 4 weeks + ergometer exercise programme (up to 2 hours daily)
Study: 18334500
Drug: Multiple regression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple regression model including treatment and covariates
Study: 18334500
Drug: Ecologic approach
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ecologic approach using grouped treatment variable
Study: 14524508
Drug: Comparison group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison group (no NMES treatment)
Study: 9352394
Drug: 0, 12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0, 12.5, 25, 50, and 100 mg triamterene
Study: 9352394
Drug: 0, 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0, 25, and 50 mg triamterene with 12.5 and 25 mg hydrochlorothiazide
Study: 3940620
Drug: Trioxifene mesylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trioxifene mesylate (5 mg, 10 mg, 20 mg orally twice daily)
Study: 3940620
Drug: Tamoxifen (previous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (previous treatment)
Study: 30046738
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DE) administered twice daily for 3 months
Study: 30046738
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) including unfractionated heparin (UFH) or low‐molecular‐weight heparin (LMWH) for 3 months
Study: 12547742
Drug: Glucosamine (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine (2,000 mg per day for 12 weeks)
Study: 8740466
Drug: Experimental hostility-reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental hostility-reduction treatment group
Study: 7072622
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g beta‐sitosterol
Study: 7072622
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g beta‐sitosteryl oleate
Study: 26511218
Drug: Postoperative low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative low-level laser therapy (LLLT) treatment for 21 days
Study: 26511218
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without postoperative laser treatment
Study: 23169523
Drug: Parenteral hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral hydration (normal saline 1 L per day)
Study: 23169523
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline 100 mL per day)